Pastori D, Sciacqua A, Marcucci R, et al. - In this prospective multicenter cohort study involving 1,735 people with nonvalvular atrial fibrillation (AF) receiving vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) from February 2008 for patients on VKA and from September 2013 for individuals on NOACs, experts predicted the prevalence of nonalcoholic fatty liver disease (NAFLD) and its influence on bleeding and thrombotic events in persons with AF. NAFLD was diagnosed in 732 of 1,735 people. No important relationship was discovered between NAFLD and cardiovascular events (CVEs). In the entire population, in comparison with VKAs, NOAC use was related to lower CVEs. Therefore, in AF, NAFLD is highly prevailing however it is not related to greater bleeding or thrombotic risk.